Ethics and Disclosure Sample Clauses

Ethics and Disclosure. I affirm the Author Representations noted below, and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, and Conflicts of Interest disclosure. Please note that some journals may require that all co-authors sign and submit Conflicts of Interest disclosure forms. I am also aware of the publisher’s policies with respect to retractions and withdrawal. I am also aware of the publisher’s policies with respect to retractions and withdrawal and the journal home page. Author representations • The article I have submitted to the journal for review is original, has been written by the stated authors and has not been published elsewhere. • The article is not currently being considered for publication by any other journal and will not be submitted for such review while under review by this journal. • The article contains no libelous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any other person or entity. • I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my article. • If I am using any personal details or images of patients or research subjects, I have obtained written permission or consent from the patient (or, where applicable, the next of kin). • If the article was prepared jointly with other authors, I have informed the co-author(s) of the terms of this publishing agreement and that I am signing on their behalf as their agent, and I am authorized to do so. DEFINITIONS Accepted Author Manuscript (“AAM”) Author’s version of the manuscript of an article that has been accepted for publication and which may include any author-incorporated changes suggested through the processes of submission processing, peer review, and editor-author communications. AAMs should not include other publisher value added contributions such as copy-editing, formatting and (if relevant) pagination, and should include the Appropriate Bibliographic Citation and a link to the final publication. Appropriate Bibliographic Citation Authors posting Accepted Author Manuscript online should later add a citation for the Published Journal Article indicating that the Article was subsequently published, and may mention the journal title provided they add the following text at the beginning of the document:
Sample 1Sample 2See All (7)
AutoNDA by SimpleDocs
Ethics and Disclosure. I confirm that I have reviewed and complied with the relevant Authors’ Instructions and agree to the Publisher’s policies, including Ethics in Publishing policy and Conflicts of Interest disclosure. In particular, I fully understand the duties of the Publisher and of the Editors and confirm that I have complied with the duties of the authors as here below noted: The Article I have submitted to the conference for review is original, has been written by the stated authors and has not been published elsewhere. The Article was not submitted elsewhere, while under review by the International Program Committee of this conference and will not be submitted to any other conference or journal. The Article and the Supplemental Materials contain no libelous or other unlawful statements and do not contain any materials that violate any personal or proprietary rights of any other person or entity. I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials. Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses and, if my or any of my co-authors’ institution has any policy that might restrict my ability to grant exclusive rights under this License Agreement, a written waiver of that policy has been obtained. If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher’s policies relating to the use of such images or personal information. Any software contained in the Supplemental Materials is free from viruses, contaminants or worms. If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.
Sample 1
Ethics and Disclosure. 3.1 The Grant Recipient shall ensure that all use of Grant funds complies with the MedTech Europe Code of Ethical Business Practice and all applicable laws and legal regulations and industry codes of conduct. Particularly, where the Grant is provided to support Healthcare Professionals’ attendance at Third Party Organised Educational Events, the Grant Recipient shall ensure that the Grant is used in accordance with Chapter 1: General Criteria for Events, of MedTech Europe Code of Ethical Business Practice, including, but not limited to, the following principles:
Sample 1
Ethics and Disclosure. I affirm the Author Representations noted below and confirm that I have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure, and information for authors from countries affected by sanctions. Please note that some journals may require that all co-authors sign and submit Declarations of Interest disclosure forms. I am also aware of the pXEOLVKHU¶V SROLFL retractions and withdrawal (xxxx://xxx.xxxxxxxx.xxx/locate/withdrawalpolicy). For further information see the publishing ethics page at xxxx://xxx.xxxxxxxx.xxx/publishingethics and the journal home page. For further information on sanctions, see: xxxxx://xxx.xxxxxxxx.xxx/about/our-business/policies/trade-sanctions. Author Representations x The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
Sample 1
Ethics and Disclosure. (a) Fxxxxx Mxx adheres to the highest standards of ethical conduct and disclosure in its interaction with government. Fxxxxx Mxx requires Contractor to comply with all applicable lobby, gift, conflict of interest, ethics, and campaign contribution statutes, laws, and regulations and to avoid any appearance of impropriety. Contractor understands that failure to comply with such laws, and with the specific provisions of this section, may result in immediate termination of this Agreement, delayed payment by Fxxxxx Mxx or other sanctions.
Sample 1
Ethics and Disclosure. If this Agreement includes services for attempting to influence government action, or any other form of lobbying, then the following are required. Please also see Section 5 of the Agreement Check If Applicable or indicate “N/A”: N/A Federal Lobbying: Contractor will timely provide Fxxxxx Mxx the amount of fees and services which are reportable as lobby activities under the Federal Lobby Disclosure Act. N/A State/Local Lobbying: Contractor will not engage in any state or local lobbying requiring registration or disclosure by Contractor or Fxxxxx Mxx under a state or local lobby law without such prior approval in a letter signed by Fannie Mae’s Business Point of Contact.
Sample 1
Ethics and Disclosure. If this Agreement includes services for attempting to influence government action, or any other form of lobbying, then the following are required. Please also see Section 5 of the Agreement Check If Applicable or indicate “N/A”: N/A Federal Lobbying: Contractor will timely provide Xxxxxx Xxx the amount of fees and services which are reportable as lobby activities under the Federal Lobby Disclosure Act. N/A State/Local Lobbying: Contractor will not engage in any state or local lobbying requiring registration or disclosure by Contractor or Xxxxxx Mae under a state or local lobby law without such prior approval in a letter signed by Xxxxxx Mae’s Business Point of Contact.
Sample 1
AutoNDA by SimpleDocs

Related to Ethics and Disclosure

  • Use and Disclosure All Confidential Information of a party will be held in confidence by the other party with at least the same degree of care as such party protects its own confidential or proprietary information of like kind and import, but not less than a reasonable degree of care. Neither party will disclose in any manner Confidential Information of the other party in any form to any person or entity without the other party’s prior consent. However, each party may disclose relevant aspects of the other party’s Confidential Information to its officers, affiliates, agents, subcontractors and employees to the extent reasonably necessary to perform its duties and obligations under this Agreement and such disclosure is not prohibited by applicable law. Without limiting the foregoing, each party will implement physical and other security measures and controls designed to protect (a) the security and confidentiality of Confidential Information; (b) against any threats or hazards to the security and integrity of Confidential Information; and (c) against any unauthorized access to or use of Confidential Information. To the extent that a party delegates any duties and responsibilities under this Agreement to an agent or other subcontractor, the party ensures that such agent and subcontractor are contractually bound to confidentiality terms consistent with the terms of this Section 11.

  • Reporting and Disclosure The Company, from time to time, shall provide government agencies with such reports concerning this Agreement as may be required by law, and the Company shall provide the Executive with such disclosure concerning this Agreement as may be required by law or as the Company may deem appropriate.

  • Publicity and Disclosure A. The Financial Agent shall not make use of any Treasury name, symbol, emblem, program name, or product name, in any advertising, signage, promotional material, press release, Web page, publication, or media interview, without the prior written consent of the Treasury.

  • Publicity and Disclosures No press releases or public disclosure, either written or oral, of the transactions contemplated by this Agreement, shall be made by a party to this Agreement without the prior knowledge and written consent of Buyer and the Company.

  • DISCLOSURE AND DISCOVERY The arbitrator may, in its discretion, allow the parties to make reasonable disclosure and discovery in regard to any matters which are the subject of the arbitration and to compel compliance with such disclosure and discovery order. The arbitrator may order the parties to comply with all or any of the disclosure and discovery provisions of the Federal Rules of Civil Procedure, as they then exist, as may be modified by the arbitrator consistent with the desire to simplify the conduct and minimize the expense of the arbitration.

  • Confidentiality and Disclosure The Local Manager and the Investment Adviser undertake to keep private and confidential all information acquired in connection with this Agreement, and not to disclose such information to any person except to the extent that:

  • Public Statements and Disclosure The initial press release concerning this Agreement and the Merger will be a joint press release reasonably acceptable to the Company and Parent and will be issued promptly following the execution and delivery of this Agreement. Thereafter, unless the Company Special Committee has made a Company Recommendation Change, the Company and its Representatives, on the one hand, and Parent and Merger Sub and their respective Representatives, on the other hand, will consult with the other Parties before (a) participating in any media interviews; (b) engaging in any meetings or calls with analysts, institutional investors or other similar Persons; or (c) providing any statements that are public or are reasonably likely to become public, in each case to the extent relating to this Agreement or the Merger and neither party shall issue any press release or make any public announcement or statement without the consent of the other party, which shall not be unreasonably withheld, conditioned or delayed; provided, that to the extent such release or announcement is required by applicable Law or any listing agreement with or rule of any national securities exchange or association upon which the securities of the Company are listed, the party required to make the release, announcement or statement shall use reasonable best efforts to consult with the other Party about, and allow the other Party reasonable time (taking into account the circumstances) to comment on, such release, announcement or statement in advance of such issuance. Notwithstanding the foregoing, neither Parent nor the Company will be obligated to engage in such consultation with respect to communications that are (i) principally directed to its employees, drivers, suppliers, customers, partners or vendors so long as such communications are consistent with prior communications previously agreed to by Parent and the Company and do not add additional material information not included in such previous communication (in which case such communications may be made consistent with such plan); (ii) related to a Superior Proposal or Company Recommendation Change or, in each case, any action taken pursuant thereto; (iii) with respect to any dispute or Legal Proceeding solely among the Parties or their respective Affiliates related to this Agreement or the Transaction Documents; or (iv) substantively consistent with previous public disclosures made by the Parties in compliance with this Section 6.13 and which do not add additional material information not included in such previous disclosure. Parent will not be obligated to engage in such consultation with respect to communications that are principally directed to its existing or prospective equity holders and investors of Parent or its Affiliates, so long as such communications are consistent with prior communications previously agreed to by Parent and the Company and do not add additional material information not included in such previous communication.

  • Preservation and Disclosure of Lists The Trustee shall preserve, in as current a form as is reasonably practicable, all information as to the names and addresses of the Holders contained in the most recent list furnished to it as provided in Section 5.01 or maintained by the Trustee in its capacity as Note Registrar, if so acting. The Trustee may destroy any list furnished to it as provided in Section 5.01 upon receipt of a new list so furnished.

  • Press Releases and Disclosure The Company may issue a press release describing the material terms of the transactions contemplated hereby as soon as practicable following the date of this Agreement, and may file with the Commission a Current Report on Form 8-K, with this Agreement attached as an exhibit thereto, describing the material terms of the transactions contemplated hereby, and the Company shall consult with the Agent prior to making such disclosures, and the parties hereto shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosures that is reasonably satisfactory to all parties hereto. No party hereto shall issue thereafter any press release or like public statement (including, without limitation, any disclosure required in reports filed with the Commission pursuant to the Exchange Act) related to this Agreement or any of the transactions contemplated hereby without the prior written approval of the other party hereto, except as may be necessary or appropriate in the reasonable opinion of the party seeking to make disclosure to comply with the requirements of applicable law or stock exchange rules. If any such press release or like public statement is so required, the party making such disclosure shall consult with the other party prior to making such disclosure, and the parties shall use all commercially reasonable efforts, acting in good faith, to agree upon a text for such disclosure that is reasonably satisfactory to all parties hereto.

  • Permitted Use and Disclosures Each Party hereto may use or disclose Confidential Information disclosed to it by the other Party to the extent such information is included in the Pharmacopeia Technology, Schering Technology or Collaboration Technology, as the case may be, and to the extent (i) such use or disclosure is reasonably necessary and permitted in the exercise of the rights granted hereunder in filing or prosecuting patent applications, prosecuting or defending litigation, (ii) such disclosure is reasonably required to be made to any institutional review board of any entity conducting clinical trials with Agreement Compound(s) and/or Agreement Product(s), or to any governmental or other regulatory agency, in order to gain approval to conduct clinical trials or to market Agreement Compound(s) and/or Agreement Products, (iii) such disclosure is required by law, regulation, rule, act or order of any governmental authority, court, or agency, or is made in connection with submitting required information to tax or other governmental authorities, or (iv) such disclosure or use is reasonably required in conducting clinical trials, or making a permitted sublicense or otherwise exercising license rights expressly granted to it by the other Party pursuant to the terms of this Agreement; in each case, provided that if a Party is required to make any such disclosure of another Party’s Confidential Information, other than pursuant to a confidentiality agreement, it will give reasonable advance notice to the other Party of such disclosure and, save to the extent inappropriate in the case of patent applications, will use its reasonable diligent efforts to secure confidential treatment of such Confidential Information in consultation with the other Party prior to its disclosure (whether through protective orders or otherwise) and disclose only the minimum necessary to comply with such requirements.

Time is Money Join Law Insider Premium to draft better contracts faster.